USANA HEALTH SCIENCES (USNA) Company Report

Kevin Guest has returned as Chief Executive Officer while retaining his role as Chairman of the Board.
For fiscal year 2026, USANA Health Sciences projects consolidated net sales growth of 4% at the midpoint, primarily driven by its venture companies, Rise Wellness and Hiya. The company also anticipates an effective income tax rate between 55% and 60% for fiscal 2026.
The company is focusing on expanding omni-channel reach, advancing product innovation, accelerating technology modernization, and scaling Rise Wellness performance. Inventory increased by $35 million (48%) to $107 million at the end of fiscal 2025 to support growth initiatives for Rise Wellness and Hiya.
A cost realignment in Q4 2025 impacted approximately 10% of the workforce, resulting in an estimated $10+ million in savings, primarily within SG&A.

Feb 18, 2026, 4:00 PM

Transcript

USANA Health Sciences Announces Q4 2025 Results and FY 2026 Outlook

USNA

Guidance Update

Management Change

New Projects/Investments

Kevin Guest has returned as CEO while continuing as Chairman, outlining a strategic focus on strengthening global brand positioning, enhancing customer experience, reinvigorating sales, advancing product innovation, improving operational efficiencies, and accelerating technology modernization.
For fiscal year 2026, USANA Health Sciences anticipates net sales growth of 4% at the midpoint, with growth driven by venture companies Rise Wellness and Hiya. The outlook reflects a 52-week fiscal year, one less week than fiscal 2025.
The company expects an effective income tax rate between 55% and 60% for fiscal year 2026. A cost realignment in Q4 2025 impacted approximately 10% of the workforce, resulting in over $10 million in net savings primarily in SG&A, which will be repurposed for strategic initiatives.
Inventory increased by $35 million or 48% to $107 million at the end of fiscal 2025, largely to support growth opportunities for Rise Wellness and Hiya, with Rise Wellness expected to operate at approximately break-even in fiscal 2026.

Feb 18, 2026, 4:00 PM

Transcript

USANA Health Sciences Announces Q4 and FY 2025 Results, Provides FY 2026 Outlook

USNA

CEO Change

Guidance Update

Layoffs

Kevin Guest has returned as Chairman and CEO of USANA Health Sciences.
USANA projects 4% net sales growth at the midpoint for fiscal year 2026.
Inventory increased by $35 million or 48% to $107 million at the end of fiscal 2025, primarily driven by growth initiatives for Rise Wellness and Hiya.
The company anticipates an effective income tax rate between 55% and 60% for fiscal 2026.
A recent cost realignment impacted 10% of the workforce, resulting in over $10 million in net savings, primarily in SG&A.

Feb 18, 2026, 4:00 PM

Transcript

USANA Health Sciences Reports Q4 and Full Year 2025 Results, Provides 2026 Outlook

USNA

Earnings

Guidance Update

Demand Weakening

USANA Health Sciences reported Q4 2025 net sales of $226.2 million and a net loss of $1.8 million (diluted EPS of -$0.10), primarily due to a $7.0 million non-cash impairment charge and $6.5 million cost realignment charges. For FY 2025, net sales reached $925.3 million, with net earnings of $10.8 million and diluted EPS of $0.58.
The company issued a Fiscal Year 2026 outlook, projecting consolidated net sales between $925 million and $1.0 billion, net earnings between $20.3 million and $26.6 million, and diluted EPS between $1.11 and $1.45.
FY 2025 net sales grew 8%, driven by contributions from Hiya and Rise Wellness, which offset an 8% decline in the core nutritional business. For FY 2026, Hiya net sales are expected to grow 6% to 17%, and Rise Wellness net sales are anticipated to accelerate by 300% to 390%, while the core nutritional business is projected to decline 0-5%.
In fiscal 2025, USANA repurchased 927,000 shares for $28 million, with $34 million remaining under the current share repurchase authorization as of January 3, 2026.

Feb 18, 2026, 1:33 AM

8-K

USANA Health Sciences Reports Q4 and Full Year 2025 Results and Provides Fiscal Year 2026 Outlook

USNA

Earnings

Guidance Update

Share Buyback

USANA Health Sciences reported net sales of $226.2 million for Q4 2025 and a net loss of $1.8 million, resulting in diluted EPS of -$0.10. For the full fiscal year 2025, net sales were $925.3 million and net earnings were $10.8 million, with diluted EPS of $0.58.
The Q4 2025 net loss was primarily influenced by a $7.0 million non-cash impairment charge and a $6.5 million charge related to cost realignment initiatives.
For fiscal year 2026, the company projects consolidated net sales between $925 million and $1.0 billion, net earnings between $20.3 million and $26.6 million, and diluted EPS between $1.11 and $1.45.
The company ended fiscal year 2025 with $158 million in cash and cash equivalents and $14 million of debt , and repurchased 927,000 shares for $28 million during the year.

Feb 17, 2026, 9:15 PM

Press Release

USANA Health Sciences projects 2026 growth driven by acquisitions and announces CEO change

USNA

Guidance Update

M&A

CEO Change

USANA Health Sciences projects mid-single-digit sales growth for 2026, aiming for nearly $1 billion in revenue, with a significant portion of this growth driven by its M&A offerings outside the core business.
The Rise Wellness acquisition is a key growth driver, with projected revenue of $65-$80 million in 2026, up from $16 million in 2025 and $5 million in 2024, largely due to the success of its Protein Pop product and expansion into major retailers like Target and Costco.
The HYA acquisition is also contributing significantly, with expected revenue of $140-$155 million in 2026, up from $132 million in 2025, supported by entry into retail channels and expansion into Canada and the United Kingdom in Q1.
The non-direct selling (omnichannel) portion of the business is rapidly growing, projected to account for low 20s% of total revenue in 2026, compared to approximately 16% in 2025 and being negligible in 2024.
Kevin Guest has transitioned back into the CEO role to reinvigorate the core direct selling business, which faces challenges and is expected to be down mid-single digits in 2026, with cost alignment initiatives planned for rollout on February 17th.

Jan 12, 2026, 8:30 PM

Transcript

USANA Health Sciences Discusses 2026 Outlook and Strategic Growth Drivers

USNA

Guidance Update

M&A

CEO Change

USANA Health Sciences anticipates mid-single-digit growth for 2026, targeting nearly $1 billion in revenue, with a significant portion of this growth coming from outside its core business.
The Rise Wellness segment is projected to grow from over $16 million in 2025 to between $65 million and $80 million in 2026, largely due to the success and expanded distribution of Protein Pop in retailers like Target and Costco.
The Hiya segment is expected to reach $140 million to $155 million in 2026, up from an estimated $132 million in 2025, driven by entry into retail channels and expansion into Canada and the United Kingdom in Q1 2026.
The non-direct selling portion of the business is forecasted to contribute 16% of revenue in 2025, increasing to the low 20s% in 2026.
Kevin Guest was recently appointed as the new CEO, returning to the role to reinvigorate the core direct selling business.

Jan 12, 2026, 8:30 PM

Transcript

USANA Health Sciences Provides Preliminary FY 2025 Net Sales and Initial FY 2026 Outlook

USNA

Guidance Update

Revenue Acceleration/Inflection

New Projects/Investments

USANA Health Sciences reported preliminary fiscal year 2025 net sales of approximately $925 million, surpassing its most recent guidance of $920 million.
The company provided an initial fiscal year 2026 net sales outlook ranging from $925 million to $1.0 billion.
This 2026 outlook projects sales of $720 to $765 million for the core nutritional business, $140 to $155 million for Hiya, and $65 to $80 million for Rise Wellness.
Rise Wellness is expected to experience accelerated growth in fiscal 2026, with operating margins projected to be at breakeven due to strategic investments.

Jan 12, 2026, 11:29 AM

8-K

USANA Provides Preliminary FY 2025 Net Sales and Initial FY 2026 Outlook

USNA

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

USANA Health Sciences announced preliminary fiscal year 2025 consolidated net sales of approximately $925 million, which is ahead of its most recently issued guidance of $920 million.
The company issued an initial net sales outlook for fiscal year 2026 in the range of $925 million to $1.0 billion.
This 2026 outlook includes net sales from its core nutritional business (USANA) of $720 to $765 million, Hiya of $140 to $155 million, and Rise Wellness of $65 to $80 million.
Fiscal year 2026 is a 52-week year, which means one less week of net sales compared to fiscal 2025, impacting the core nutritional business.
USANA is making meaningful investments in inventory, capital expenditures, and working capital to support the early growth stages of Rise Wellness and Hiya.

Jan 12, 2026, 11:15 AM

Press Release

USANA Health Sciences Announces CEO Transition

USNA

CEO Change

Management Change

Kevin Guest has returned to USANA Health Sciences, Inc. as Chief Executive Officer, effective January 8, 2026, and will continue to serve as Chairman.
Jim Brown has stepped down from his position as CEO and President, but will remain with the Company in an advisory role.
Mr. Guest previously served as CEO from 2015 to 2023 and as Executive Chairman for the past three years.
The Compensation Committee has not yet determined the material terms of compensation for either Mr. Brown or Mr. Guest in connection with these changes.